SLC5A2 and ischemic cardiomyopathy: One possible explanation is that patients with established ASCVD may develop ischemic cardiomyopathy associated with lower cardiac functions [56], since the diuretic and natriuretic effects of the SGLT2 inhibitor that improve preload and afterload have become relatively restricted.